Research

With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.

LATEST NEWS

  • August 13, 2018SNMMI Honors Outstanding Contributors at 2018 Annual Meeting
    The Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization, recognized contributions to the field of nuclear medicine and molecular imaging during its 2018 Annual Meeting in Philadelphia. Several awards ceremonies were held to recognize the valuable role SNMMI members play in advancing the diagnosis and treatment of heart disease, cancer and neurological conditions.
  • August 6, 2018PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
    In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the metastases. However, little is known about ER expression across metastases throughout the body and surrounding normal tissue. Using a PET tracer, researchers in the Netherlands have been able to identify differences in ER expression, which could help guide treatment for metastatic breast cancer patients. The study is featured in The Journal of Nuclear Medicine’s August issue.
  • August 2, 2018Novel PET Imaging Method Could Track and Guide Therapy for Type 1 Diabetes
    Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The new PET imaging method could measure beta-cell mass, which would greatly enhance the ability to monitor and guide diabetes therapies. This study is reported in the featured article of the month in The Journal of Nuclear Medicine’s August issue.
  • July 9, 2018Novel PET Imaging Method More Fully Evaluates Extent of Rheumatoid Arthritis Inflammation
    A new PET imaging method more fully evaluates the extent of rheumatoid arthritis by targeting translocator protein (TSPO) expression in the synovium (joint lining tissue). The study is featured in the July issue of The Journal of Nuclear Medicine.
  • July 2, 2018Novel Pretargeted Radionuclide Therapy for HER2-Expressing Cancers Shows Promise
    In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth factor receptor 2)-expressing cancers is non-toxic to the kidneys and improves survival. The study is reported in The Journal of Nuclear Medicine’s July featured article of the month.
  • June 28, 2018SNMMI 65th Annual Meeting Sets the Stage for a Revolution in Precision Medicine
    More than 5,000 physicians, technologists, scientists and exhibitors gathered for the Society of Nuclear Medicine and Molecular Imaging’s 65th Annual Meeting, held June 23-26 in Philadelphia. With nuclear medicine playing a growing role in providing precision medicine, theranostics (combining diagnostic imaging and targeted radionuclide therapy) were an important focus throughout the meeting.
  • June 26, 2018Fluciclovine PET/CT Locates Recurrent Prostate Cancer and Advises Management
    The addition of fluorine-18-fluciclovine PET/CT to the diagnostic work-up of patients with biochemical recurrence of prostate cancer locates previously undetected lesions and changes treatment management for the majority of patients, according to a clinical trial report presented at the SNMMI 2018 Annual Meeting.
  • June 26, 2018Early Treatment of Advanced Prostate Cancer with PSMA-Targeted Radioligand Therapy Prolongs Life
    Research presented at the SNMMI 2018 Annual Meeting demonstrates for the first time the benefit of providing earlier lutetium-177 prostate-specific membrane antigen (PSMA) radioligand therapy to patients with metastatic prostate cancer. Until now, this therapy has only been used in patients with end-stage disease.

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities.  Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.